Last reviewed · How we verify

NCT05784948

Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis

Completed NA Last updated 10 April 2023
What this trial tests

NA trial testing Virtual Reality Mindfulness Treatment in Schizophrenia Spectrum Disorders in 67 participants. Completed in 9 June 2021.

Timeline
8 April 2020
Primary endpoint
9 June 2021
9 June 2021

Quick facts

Lead sponsorChonbuk National University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment67
Start date8 April 2020
Primary completion9 June 2021
Estimated completion9 June 2021
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Chonbuk National University Hospital

Who can join

Adults 15 to 59, any sex, with Schizophrenia Spectrum Disorders or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the safety and efficacy of Virtual Reality Mindfulness in Patients With Psychosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Schizophrenia Spectrum Disorders

Currently open trials in the same condition.

Other Chonbuk National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05784948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing